Fezolinetant is contraindicated in individuals using CYP1A2 inhibitors. Fezolinetant is a substrate of CYP1A2 and concomitant use with drugs that are weak, moderate, or strong CYP1A2 inhibitors increases the maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) of fezolinetant
Clinical studies and model-informed approaches6
In vitro studies6
Transporter systems6
Data on file.
Epocrates®. CYP450 Enzyme and P-gp Transporter Inhibitor Check. Available at: https://www.epocrates.com/.
UpToDate® LexiDrugTM. Interactions. Available at: https://online.lexi.com.
Drugs.com®. Interaction Checker. Available at: https://www.drugs.com.
Micromedex® Pharmaceutical Knowledge. Available at: https://www.micromedexsolutions.com
VEOZAH [package insert]. Northbrook, IL, USA: Astellas Pharma, Inc. Available at: https://www.astellas.com/us/system/files/veozah_uspi.pdf.
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here